Maravai LifeSciences Cash Flow Statement
NASDAQ: MRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
7.44+0.23 (+3.19%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Maravai LifeSciences free cash flow
In fiscal 2025, Maravai LifeSciences generated -$57.6 million of operating cash flow and spent $13.1 million on capital expenditures. That left free cash flow of -$70.7 million, a free-cash-flow margin of -38.1% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Maravai LifeSciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Net Income | -230.76M | -259.62M | -138.38M | 490.66M | 469.25M | 78.82M | -5.20M |
| Net Income growth (YoY) | — | — | -128.20% | +4.56% | +495.37% | — | — |
| Depreciation & Amortization | 23.56M | 20.85M | 12.90M | 7.57M | 6.41M | 5.59M | 3.81M |
| Stock-Based Compensation | 30.17M | 49.41M | 34.59M | 18.67M | 10.46M | 24.63M | 1.68M |
| Change in Working Capital | 9.02M | -9.11M | 106.80M | -48.91M | -172.11M | 38.41M | 2.29M |
| Operating Cash Flow | -57.57M | 7.46M | 126.22M | 535.98M | 368.57M | 152.19M | 24.11M |
| Capital Expenditures | -13.15M | -29.66M | -65.55M | -17.09M | -14.85M | -25.41M | -17.15M |
| Investing Cash Flow | -31.41M | -24.32M | -122.31M | -267.61M | 105.66M | 6.07M | -17.15M |
| Share Repurchases | — | — | — | 0 | 0 | -33.66M | 0 |
| Debt Issued | — | 953.00K | 0 | 8.46M | 0 | 609.00M | 0 |
| Debt Repaid | -5.44M | -234.39M | -5.44M | -13.89M | -6.00M | -411.88M | -2.50M |
| Financing Cash Flow | -16.50M | -235.71M | -61.09M | -187.50M | -159.05M | 53.21M | -4.17M |
| Net Change in Cash | -105.51M | -252.56M | -57.18M | 80.87M | 315.09M | 211.48M | 2.83M |
| Free Cash Flow | -70.72M | -22.19M | 60.67M | 518.89M | 353.72M | 126.78M | 6.97M |
This table shows 7 annual periods of Maravai LifeSciences's cash flow statement, from FY 2025 back to FY 2019, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MRVI's reporting calendar. What is a cash flow statement?